The decision was based on an interim analysis of the phase 3 Opera-T study, conducted after around half of the patients had ...

A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital ...

Soley Therapeutics has secured $200 million in series C funds, which the artificial-intelligence-enabled biotech plans to use ...

Rakuten Medical has added to its tally of mega-rounds, pocketing another $100 million to push its lead light-based cancer ...

Amgen is getting down with Disco Pharmaceuticals, commissioning the German biotech to work on cancer therapies focused on a ...

Staar Surgical will remain independent after a bitter shareholder battle that has raged for the past several months has now ...

GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, ...

Basilea Pharmaceutica is continuing its quest to develop much-needed new antifungal drugs by penning a deal with Prokaryotics ...

Hutchmed has continued to test sovleplenib in wAIHA in parallel, culminating in the delivery of data from a Chinese phase 3 ...

BrainSpace, a medtech focused on neurological injuries and illnesses, received 501 (k) clearance from the FDA for its brain ...

Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...

Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...